Tech Company Financing Transactions
Acer Therapeutics Funding Round
TVM Capital and private investors participated in a $8.2 million Series B funding round for Acer Therapeutics. The financing was announced on 5/11/2016.
Transaction Overview
Company Name
Announced On
5/11/2016
Transaction Type
Venture Equity
Amount
$8,150,000
Round
Series B
Investors
TVM Capital (Lead Investor) (Luc Marengere)
Proceeds Purpose
Proceeds from the financing will primarily be used to prepare a new drug application (NDA) for the company's lead candidate, ACER-002 (celiprolol hydrochloride), which is being developed for the treatment of vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening genetic connective tissue disorder.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Gateway Center 300 Washington St. 351
Newton, MA 02458
USA
Newton, MA 02458
USA
Phone
Website
Email Address
Overview
Acer Therapeutics is developing therapies with established clinical proof-of-concept for the treatment of serious, ultra-rare diseases with critical unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Schelling
Chief Financial Officer
Harry Palmin
Chief Medical Officer
William Andrews
Vice President
Kristin Mulready
VP - General Counsel
Donald Joseph
VP - Human Resources
Bernie Paul
VP - Manufacturing
John Klopp
VP - Marketing
Patty Pound
Browse more venture capital transactions:
Prev: 5/11/2016: Bolt Threads venture capital transaction
Next: 5/11/2016: Nearpod venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs